PubMed · 2015 · 51 citations · 14 references
MedicineEndocrinologyPharmacologyNeuroendocrinologyPsychopharmacologyReproductive EndocrinologyAntidepressant PharmacologyHypothalamic-pituitary RegulationMenopause ManagementMenopause PharmacotherapyOvarian PhysiologyStress Hormone RegulationAnimal Model EvaluationAnimal Model PharmacologyAntidepressant EfficacyAntidepressant ResponseChronic StressDepression PathophysiologyOpen-field TestStress Hormones
Paeoniflorin has been shown to effectively relieve neurologic impairments and lessen depression. It remains poorly understood whether it can be used to treat menopause depression; therefore, in the present study, animal model of menopause depression were established by resecting the ovaries in combined with long-term chronic unpredictable stress. Animal model of menopause depression was established by ovariectomy. Sprague-Dawley rats were given 10 mg/kg of paeoniflorin by gastrogavage for 2 weeks. Fluoxetine (2.5 mg/kg) served as a positive control. Sucrose solution consumption test, open-field test, real-time PCR and western blot results demonstrated that paeoniflorin increased sucrose solution consumption, voluntary behaviors and 5-HT1AR mRNA and protein expression. Paeoniflorin decreased the levels of corticotropin releasing hormone (CRH), adrenocorticotropic hormone (ACTH), cortisol (CORT) and 5-HT2AR mRNA and protein expression in rats with menopause depression. These results indicate that paeoniflorin unregulated 5-HT1AR expression, but downregulated 5-HT2AR expression in brains of rats with menopause depression, and thus exert antidepressant effects.
14
Risk for New Onset of Depression During the Menopausal Transition
Lee S. Cohen, Cláudio N. Soares, Allison F. Vitonis et al. · Archives of General Psychiatry · 2006 · 822 citations
Medicine, Endocrinology, Psychiatry +17
Juan Nácher, Daniel R. Rosell, Gregori Alonso‐Llosà et al. · European Journal of Neuroscience · 2001 · 201 citations
Medicine, Neurobiology, Neuroscience +17